.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Multiple Myeloma: Emerging Concepts in Management

EP. 1: Risk Assessment for Myeloma

January 23rd 2018

EP. 2: Managing High-Risk Smoldering Myeloma

January 23rd 2018

EP. 3: Upfront Therapy Approaches in Myeloma

January 23rd 2018

EP. 4: Upfront Combination Therapies in Myeloma

January 23rd 2018

EP. 5: Impact of Maintenance Therapy in Myeloma

January 23rd 2018

EP. 6: The Role of Transplant in Myeloma

January 23rd 2018

EP. 7: Daratumumab-Based Regimens in R/R Myeloma

January 23rd 2018

EP. 8: Impact of Elotuzumab in R/R Myeloma Therapies

January 23rd 2018

EP. 9: Adding Carfilzomib to R/R Myeloma Regimens

January 23rd 2018

EP. 10: The Role of MRD Testing in Myeloma

January 23rd 2018

EP. 11: Impact of MRD Assessment on Myeloma Treatment

January 23rd 2018

EP. 12: Other Agents for Treating Myeloma

January 23rd 2018

EP. 13: Immunotherapies in Myeloma

January 23rd 2018

EP. 14: Improving Outcomes in Myeloma

January 23rd 2018

EP. 15: Looking to the Future of Myeloma Care

January 23rd 2018